High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls
AUTOR(ES)
Romero, Gustavo Adolfo Sierra, Flores, Érico Marlon de Moraes, Noronha, Elza Ferreira, Macêdo, Vanize de Oliveira
FONTE
Memórias do Instituto Oswaldo Cruz
DATA DE PUBLICAÇÃO
2003-01
RESUMO
We analyzed data from historical controls treated with meglumine antimoniate to compare the frequency of adverse events observed in patients with cutaneous leishmaniasis treated with the same dose of meglumine antimoniate contaminated with heavy metals in an endemic area of the State of Bahia, Brazil. Group A patients were treated in 2000 with the drug produced by Eurofarma Laboratórios Ltda., São Paulo, Brazil (lot A) and group B patients were treated in 1996 with the reference drug produced by Rhodia Farma Ltda., São Paulo, Brazil (lot B). We observed an unusual higher frequency of skin reactions in group A patients. However, all type of adverse events observed in group A were also observed in group B. The physico-chemical analysis of these lots revealed that lot A had lower pH and higher concentration of total and trivalent antimony, lead, cadmium, and arsenic. Our findings suggest that the skin reactions could be attributed to heavy metal contamination of lot A.
Documentos Relacionados
- Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
- Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
- Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
- Toxic heavy metals: materials cycle optimization.
- Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate